https://orcid.org/0000-0002-4058-2215
References
- Gupta P, Bansal S, Gupta A, et al. Prevalence of arrhythmia in COVID-19 patients with mild/moderate and severe illness: a prospective cohort study. Expert Rev Cardiovasc Ther. 2023;21(6):453–461. doi: 10.1080/14779072.2023.2216456
- Wollborn J, Karamnov S, Fields KG, et al. COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Sci Rep. 2022;12(1):12014. doi: 10.1038/s41598-022-16113-6
- Li YG, Pastori D, Farcomeni A, et al. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2019;155(3):510–518. doi: 10.1016/j.chest.2018.09.011
- Meléndez GC, McLarty JL, Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56(2):225–231. doi: 10.1161/HYPERTENSIONAHA.109.148635
- Lazzerini PE, Abbate A, Boutjdir M, et al. Fir(e)ing the rhythm: inflammatory cytokines and cardiac arrhythmias. JACC Basic Transl Sci. 2023;8(6):728–750. doi: 10.1016/j.jacbts.2022.12.004
- Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169(1):62–72. doi: 10.1016/j.ijcard.2013.08.078
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499–518.
- Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. Published Correction Appears In JAMA Intern Med. 2021 Apr 1;181(4):570. JAMA Intern Med. 2021;181(1):41-51.